H. van der Voet

James Cook University Hospital

Papers

1

Total Citations

31

H-Index

1

About

H. van der Voet is a leading clinical researcher in radiation oncology, with a primary focus on prostate cancer treatment and the comparative effectiveness of stereotactic body radiotherapy (SBRT) versus surgery. Their most notable contribution is the PACE-A trial, a landmark international phase 3 randomised controlled trial that directly compared SBRT to radical prostatectomy for localised prostate cancer. This work, published in 2023 and already cited 31 times, addresses a critical gap in evidence by providing randomised data on quality-of-life outcomes, where prior studies relied on observational data. Van der Voet’s research has helped clarify the therapeutic equipoise between these two major treatment modalities, offering patients and clinicians robust evidence to guide shared decision-making. By focusing on patient-reported outcomes and treatment tolerability, their work has advanced the paradigm of personalised, less invasive cancer care. With a reputation for rigorous trial design and impactful clinical translation, van der Voet continues to shape the future of prostate cancer management through high-quality, practice-changing research.

Research Focus

Key Achievements

1
H-Index
1
Papers
31
Total Citations
31
Avg Citations/Paper
🏆 Most Cited Paper
PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.
31 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: James Cook University Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago